Industry
Biotechnology
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Loading...
Open
2.13
Mkt cap
52M
Volume
124K
High
2.17
P/E Ratio
-0.94
52-wk high
5.70
Low
2.08
Div yield
N/A
52-wk low
1.21
Portfolio Pulse from Benzinga Newsdesk
August 20, 2024 | 9:04 pm
Portfolio Pulse from Benzinga Newsdesk
August 20, 2024 | 9:03 pm
Portfolio Pulse from Benzinga Newsdesk
August 07, 2024 | 12:01 pm
Portfolio Pulse from Benzinga Newsdesk
May 14, 2024 | 10:33 am
Portfolio Pulse from Benzinga Insights
May 09, 2024 | 12:06 pm
Portfolio Pulse from Benzinga Newsdesk
May 08, 2024 | 12:02 pm
Portfolio Pulse from Benzinga Newsdesk
March 18, 2024 | 6:24 am
Portfolio Pulse from Benzinga Newsdesk
March 13, 2024 | 7:33 pm
Portfolio Pulse from Benzinga Newsdesk
March 13, 2024 | 12:04 pm
Portfolio Pulse from Benzinga Newsdesk
March 13, 2024 | 12:03 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.